123 related articles for article (PubMed ID: 20372009)
1. Estimating pediatric doses of drugs metabolized by cytochrome P450 (CYP) isozymes, based on physiological liver development and serum protein levels.
Suzuki S; Murayama Y; Sugiyama E; Hirunpanich V; Saito K; Sekiyama M; Sato H
Yakugaku Zasshi; 2010 Apr; 130(4):613-20. PubMed ID: 20372009
[TBL] [Abstract][Full Text] [Related]
2. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children.
Kanamori M; Takahashi H; Echizen H
Int J Clin Pharmacol Ther; 2002 Nov; 40(11):485-92. PubMed ID: 12698985
[TBL] [Abstract][Full Text] [Related]
3. Optimizing pediatric dosing: a developmental pharmacologic approach.
Anderson GD; Lynn AM
Pharmacotherapy; 2009 Jun; 29(6):680-90. PubMed ID: 19476420
[TBL] [Abstract][Full Text] [Related]
4. Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease.
Matsunaga N; Hattori K; Iizasa H; Kizu J; Takanaka A; Nakashima E
Biol Pharm Bull; 2001 Sep; 24(9):1037-43. PubMed ID: 11558565
[TBL] [Abstract][Full Text] [Related]
5. Prediction of cytochrome p450-mediated hepatic drug clearance in neonates, infants and children : how accurate are available scaling methods?
Björkman S
Clin Pharmacokinet; 2006; 45(1):1-11. PubMed ID: 16430308
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
Stringer RA; Strain-Damerell C; Nicklin P; Houston JB
Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
[TBL] [Abstract][Full Text] [Related]
7. Predictive Performance of Physiologically Based Pharmacokinetic (PBPK) Modeling of Drugs Extensively Metabolized by Major Cytochrome P450s in Children.
Zhou W; Johnson TN; Bui KH; Cheung SYA; Li J; Xu H; Al-Huniti N; Zhou D
Clin Pharmacol Ther; 2018 Jul; 104(1):188-200. PubMed ID: 29027194
[TBL] [Abstract][Full Text] [Related]
8. Model qualification of the PK-Sim® pediatric module for pediatric exposure assessment of CYP450 metabolized compounds.
Yun YE; Edginton AN
J Toxicol Environ Health A; 2019; 82(14):789-814. PubMed ID: 31405354
[TBL] [Abstract][Full Text] [Related]
9. Investigation of sarizotan's impact on the pharmacokinetics of probe drugs for major cytochrome P450 isoenzymes: a combined cocktail trial.
Krösser S; Neugebauer R; Dolgos H; Fluck M; Rost KL; Kovar A
Eur J Clin Pharmacol; 2006 Apr; 62(4):277-84. PubMed ID: 16525816
[TBL] [Abstract][Full Text] [Related]
10. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
Cubitt HE; Houston JB; Galetin A
Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
[TBL] [Abstract][Full Text] [Related]
11. Effects of water deprivation on drug pharmacokinetics: correlation between drug metabolism and hepatic CYP isozymes.
Lee JH; Oh JM; Lee MG
Arch Pharm Res; 2008 Aug; 31(8):951-64. PubMed ID: 18787780
[TBL] [Abstract][Full Text] [Related]
12. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
Alcorn J; McNamara PJ
Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase.
Masubuchi Y; Hosokawa S; Horie T; Suzuki T; Ohmori S; Kitada M; Narimatsu S
Drug Metab Dispos; 1994; 22(6):909-15. PubMed ID: 7895609
[TBL] [Abstract][Full Text] [Related]
15. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
16. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
Bartelink IH; Rademaker CM; Schobben AF; van den Anker JN
Clin Pharmacokinet; 2006; 45(11):1077-97. PubMed ID: 17048973
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol.
Guitton J; Buronfosse T; Desage M; Flinois JP; Perdrix JP; Brazier JL; Beaune P
Br J Anaesth; 1998 Jun; 80(6):788-95. PubMed ID: 9771309
[TBL] [Abstract][Full Text] [Related]
18. Cytochrome P450 mediated-drug metabolism is reduced in children with sepsis-induced multiple organ failure.
Carcillo JA; Doughty L; Kofos D; Frye RF; Kaplan SS; Sasser H; Burckart GJ
Intensive Care Med; 2003 Jun; 29(6):980-984. PubMed ID: 12698250
[TBL] [Abstract][Full Text] [Related]
19. Gender-related differences in pharmacokinetics and their clinical significance.
Tanaka E
J Clin Pharm Ther; 1999 Oct; 24(5):339-46. PubMed ID: 10583696
[TBL] [Abstract][Full Text] [Related]
20. Prediction of Human Hepatic Clearance for Cytochrome P450 Substrates via a New Culture Method Using the Collagen Vitrigel Membrane Chamber and Fresh Hepatocytes Isolated from Liver Humanized Mice.
Watari R; Kakiki M; Yamasaki C; Ishida Y; Tateno C; Kuroda Y; Ishida S; Kusano K
Biol Pharm Bull; 2019; 42(3):348-353. PubMed ID: 30828066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
